PT  - JOURNAL ARTICLE
AU  - Navarro-Triviño, Francisco J
AU  - Llamas-Molina, Jose Maria
AU  - Ayen-Rodriguez, Angela
AU  - Cancela-Díez, Barbara
AU  - Ruiz-Villaverde, Ricardo
TI  - Dramatic improvement of bullous pemphigoid with omalizumab in an elderly patient
AID  - 10.1136/ejhpharm-2020-002418
DP  - 2021 Nov 01
TA  - European Journal of Hospital Pharmacy
PG  - 350--352
VI  - 28
IP  - 6
4099  - http://ejhp.bmj.com/content/28/6/350.short
4100  - http://ejhp.bmj.com/content/28/6/350.full
SO  - Eur J Hosp Pharm2021 Nov 01; 28
AB  - A 70-year-old man with a history of hypertension was evaluated in our dermatology department due to the appearance of a clinical picture compatible with bullous pemphigoid that was confirmed histologically. The lack of response to topical and systemic immunosuppressive treatment resulted in omalizumab being prescribed in a multidisciplinary committee based on the clinical and analytical findings and the patient’s refusal to be treated with rituximab. The evaluation at 3 months showed the absence of blisters on the clinical examination. No associated adverse effects were observed. In the following 3 months the patient was administered medication at home in the absence of an anaphylactic reaction and with prior training by the nursing staff of the Hospital Pharmacy Service. After 6 months the medication was suspended with no relapses for 6 months since the last dose. Omalizumab, an anti-IgE monoclonal drug which has a good safety profile with minimum adverse side effects should be considered when there is a contraindication to the use of intravenous therapies (eg, immunoglobulins, rituximab) or prolonged immunosuppressive treatment (eg, methotrexate, azathioprine).All data relevant to the study are included in the article.